Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

With Robert F. Kennedy Jr. set to be sworn in as HHS secretary later Thursday, one of the first tasks in his new position ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, provided progress updates on its Phase 1b, 12-week ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Several small biotechs working on new treatments for weight loss believe that developing therapies with mechanism of actions not seen with current drugs, such as those from Novo Nordisk (NVO) and Eli ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Sleep-apnoea-tackling Resmed is dreaming big but the question is: what can upset the Aussie biotech's growth story?